{"id":1914,"date":"2010-11-01T12:05:00","date_gmt":"2010-11-01T11:05:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2010\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko"},"modified":"2010-11-01T12:05:00","modified_gmt":"2010-11-01T11:05:00","slug":"statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2010\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko","title":{"rendered":"Statine in der kardiovaskul\u00e4ren Prim\u00e4rpr\u00e4vention \u2013 kein Nutzen bei niedrigem Risiko"},"content":{"rendered":"<p>Der g\u00fcnstige Effekt der Statine in der Sekund\u00e4rpr\u00e4vention \u2013 also bei Patienten mit manifester kardiovaskul\u00e4rer Erkrankung \u2013 ist unumstritten. Nicht so eindeutig ist die Studienlage zu ihrem Einsatz in der Prim\u00e4rpr\u00e4vention, zumal es nur wenige Studien gibt, in denen tats\u00e4chlich nur Probanden untersucht wurden, die keine kardiovaskul\u00e4ren Vorerkrankungen hatten. Deshalb f\u00fchrte eine internationale Arbeitsgruppe eine [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Der g\u00fcnstige Effekt der Statine in der Sekund\u00e4rpr\u00e4vention \u2013 also bei Patienten mit manifester kardiovaskul\u00e4rer Erkrankung \u2013 ist unumstritten. Nicht so eindeutig ist die Studienlage zu ihrem Einsatz in der Prim\u00e4rpr\u00e4vention, zumal es nur wenige Studien gibt, in denen tats\u00e4chlich nur Probanden untersucht wurden, die keine kardiovaskul\u00e4ren Vorerkrankungen hatten. Deshalb f\u00fchrte eine internationale Arbeitsgruppe eine [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[4137,1135,495,4136,2461,1046,4128,451,449,1166,71,455,453,4139,2997,498,456,454,892,65,1167,801,4138,3126,1043,505,443,3333],"class_list":["post-1914","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-afcaps-studie","tag-allhat-studie","tag-angina-pectoris","tag-ascot-studie","tag-aspen-studie","tag-atorvastatin","tag-cards-studie","tag-cholesterinsynthese-hemmer","tag-cse-hemmer","tag-fluvastatin","tag-herzinfarkt","tag-hmg-coa-reduktase-hemmer","tag-hypercholesterinaemie","tag-hyrim-studie","tag-jupiter-studie","tag-koronare-herzkrankheit","tag-lipidsenker","tag-lovastatin","tag-mega-studie","tag-myokardinfarkt","tag-pitavastatin","tag-pravastatin","tag-prevend-it-studie","tag-prosper-studie","tag-rosuvastatin","tag-simvastatin","tag-statine","tag-woscops-studie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1914","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1914"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1914\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1914"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1914"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1914"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}